Literature DB >> 20101723

Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.

Alex L Lublin1, Sam Gandy.   

Abstract

Alzheimer's disease is the most common form of senile dementia. Although the amyloid-beta peptide was identified in 1984 as the major constituent of the senile plaques that characterize the disease, accumulating evidence indicates that the plaque density does not correspond well to the concurrent disease state. In order to resolve this disconnect, a number of recent studies have shifted away from the senile plaque and classical fibrillar forms of amyloid toward a less well structured species as the proximate neurotoxic factor underlying cognitive failure in Alzheimer's disease: soluble amyloid-beta peptide oligomer (also known as the amyloid-beta peptide-derived diffusible ligand). Paradoxically, several studies in the last 2 years have shown that picomolar levels of amyloid-beta peptide have neutral activity or perhaps even an essential role in learning and memory. Here we highlight some of the key observations underlying the growing focus on the amyloid-beta peptide oligomer. (c) 2010 Mount Sinai School of Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101723      PMCID: PMC3306842          DOI: 10.1002/msj.20160

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  20 in total

1.  Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice.

Authors:  Judit España; Lydia Giménez-Llort; Jorge Valero; Alfredo Miñano; Alberto Rábano; José Rodriguez-Alvarez; Frank M LaFerla; Carlos A Saura
Journal:  Biol Psychiatry       Date:  2009-08-07       Impact factor: 13.382

2.  Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity.

Authors:  Anja Harmeier; Christian Wozny; Benjamin R Rost; Lisa-Marie Munter; Haiqing Hua; Oleg Georgiev; Michael Beyermann; Peter W Hildebrand; Christoph Weise; Walter Schaffner; Dietmar Schmitz; Gerd Multhaup
Journal:  J Neurosci       Date:  2009-06-10       Impact factor: 6.167

3.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

4.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.

Authors:  Summer L Bernstein; Nicholas F Dupuis; Noel D Lazo; Thomas Wyttenbach; Margaret M Condron; Gal Bitan; David B Teplow; Joan-Emma Shea; Brandon T Ruotolo; Carol V Robinson; Michael T Bowers
Journal:  Nat Chem       Date:  2009-07       Impact factor: 24.427

5.  Beta-amyloid monomers are neuroprotective.

Authors:  Maria Laura Giuffrida; Filippo Caraci; Bruno Pignataro; Sebastiano Cataldo; Paolo De Bona; Valeria Bruno; Gemma Molinaro; Giuseppe Pappalardo; Angela Messina; Angelo Palmigiano; Domenico Garozzo; Ferdinando Nicoletti; Enrico Rizzarelli; Agata Copani
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

6.  Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization.

Authors:  Megan M Murray; Summer L Bernstein; Vy Nyugen; Margaret M Condron; David B Teplow; Michael T Bowers
Journal:  J Am Chem Soc       Date:  2009-05-13       Impact factor: 15.419

7.  Amyloid beta mediates memory formation.

Authors:  Ana Garcia-Osta; Cristina M Alberini
Journal:  Learn Mem       Date:  2009-03-24       Impact factor: 2.460

8.  Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus.

Authors:  Daniela Puzzo; Lucia Privitera; Elena Leznik; Mauro Fà; Agnieszka Staniszewski; Agostino Palmeri; Ottavio Arancio
Journal:  J Neurosci       Date:  2008-12-31       Impact factor: 6.167

9.  Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake.

Authors:  Shaomin Li; Soyon Hong; Nina E Shepardson; Dominic M Walsh; Ganesh M Shankar; Dennis Selkoe
Journal:  Neuron       Date:  2009-06-25       Impact factor: 17.173

10.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11
View more
  43 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Authors:  Sam Gandy; Adam J Simon; John W Steele; Alex L Lublin; James J Lah; Lary C Walker; Allan I Levey; Grant A Krafft; Efrat Levy; Frédéric Checler; Charles Glabe; Warren B Bilker; Ted Abel; James Schmeidler; Michelle E Ehrlich
Journal:  Ann Neurol       Date:  2010-08       Impact factor: 10.422

Review 3.  Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics.

Authors:  Anuradha Kalani; Alka Tyagi; Neetu Tyagi
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 4.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Testing the amyloid hypothesis of Alzheimer's disease in vivo.

Authors:  Sam Gandy
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

7.  BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.

Authors:  Yan Cai; Xue-Mei Zhang; Lauren N Macklin; Huaibin Cai; Xue-Gang Luo; Salvatore Oddo; Frank M Laferla; Robert G Struble; Gregory M Rose; Peter R Patrylo; Xiao-Xin Yan
Journal:  Neurotox Res       Date:  2011-07-02       Impact factor: 3.911

8.  Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes.

Authors:  Elaine Delvaux; Karen Bentley; Victoria Stubbs; Marwan Sabbagh; Paul D Coleman
Journal:  Neurobiol Aging       Date:  2013-01-05       Impact factor: 4.673

Review 9.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

10.  Conditional BDNF Delivery from Astrocytes Rescues Memory Deficits, Spine Density, and Synaptic Properties in the 5xFAD Mouse Model of Alzheimer Disease.

Authors:  Benoit de Pins; Carmen Cifuentes-Díaz; Amel Thamila Farah; Laura López-Molina; Enrica Montalban; Anna Sancho-Balsells; Ana López; Silvia Ginés; José María Delgado-García; Jordi Alberch; Agnès Gruart; Jean-Antoine Girault; Albert Giralt
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.